ENHO and obesity disorder: Its expression was declined in the liver with genetically induced obesity or high-fat diet (HFD)-induced obesity, transgenic overexpression or systemic adropin treatment protects against hepatic steatosis, and hyperinsulinemia associated with obesity; therefore, adropin acts as a positive factor governing glucose and lipid homeostasis [80, 81].